Patent Applications

 

TIDMONG 
 
RNS Number : 9011K 
Oxford Nutrascience Group PLC 
28 April 2010 
 

28 April 2010 
International patent applications made for Chewitab(TM),  novel gels, syrups and 
                               suspension systems 
Oxford Nutrascience Group plc ("Oxford Nutrascience" or "the Company") announces 
that it has filed two international patent applications. The submission of the 
patents, which are in line with the milestones as outlined in the Company's 
admission document dated 8 February 2010, will cover more than 130 countries. 
 
PCT application no PCT/GB2010/050674, entitled "Chewable Oral Delivery System", 
covers the novel chewable tablet technology for vitamins and medicines developed 
by the Company. Initially the Company intends to launch of a range of 
Chewitab(TM) products including a chewable calcium supplement and a chewable 
multi-vitamin supplement. It will also be seeking to license its tablet 
technology to major consumer healthcare companies in the global over-the-counter 
(OTC) and prescription pharmaceutical sectors 
 
PCT application no PCT/GB2010/050673, entitled "Delivery System", covers the 
novel gels, syrups and suspension systems developed by Oxford Nutrascience. 
These products will also be commercialised by licensing the Company's 
intellectual property to major brand owners in the OTC and prescription 
pharmaceutical sectors. 
 
Both applications claim priority from the delivery system patent application 
which Oxford Nutrascience filed in April 2009. They are expected to be published 
in October 2010. Following initial examination in the international phase, these 
will, in due course be turned into national and regional patent applications in 
the countries of interest. 
 
Marcelo Bravo, Executive Chairman and Chief Technology Officer commented, 
 
"These two international patent applications are an important step in the 
continued advancement of the commercialisation of our technology. 
 
"We now have two very robust patent applications for the business's key 
technologies, namely chewable tablets and liquid suspensions and gels. Both 
these technologies deliver unique advantages in dispersion and solubilisation of 
medicines, improved taste and mouth feel and manufacturing process 
simplification." 
                                    - Ends - 
For further information: 
www.oxfordnutrascience.com 
 
Oxford Nutrascience Group Plc 
Nigel Theobald, Chief Executive                        [phone] 
Mark Way, Investor and Media Relations           [phone] 
 
ZAI Corporate Finance (Nominated Adviser) 
Ray Zimmerman                                              [phone] 
Sarang Shah                                                   [phone] 
 
 
About Oxford Nutrascience Group Plc 
 
·      Oxford Nutrascience is a UK consumer healthcare company that develops 
chewy confectionery, chewable tablets and liquid suspensions to allow medicines 
and vitamin supplements to be taken in a more pleasant and convenient way. 
 
·      Oxford Nutrascience has developed technology for the use of prebiotic 
soluble fibres in medicine delivery systems that disperse and solubilise 
medicines, improve taste and mouth feel, simplify processing and eliminate 
additives, incorporate prebiotic health benefits. 
 
·      Chews: Oxford Nutrascience currently produces Ellactiva , a calcium chewy 
supplement sold in the UK and in the Middle East, and plans to launch new chews 
to complement this existing product. 
 
·      Chewable tablets and liquid suspensions: The target market for Oxford 
Nutrasciences' Chewitabs(TM) and liquid suspension delivery systems are 
over-the-counter ("OTC") pain relieving drugs, indigestion preparations and 
cough and cold medicines. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCPGURCCUPUGAM